Hypothesis
Individuals with low baseline RMSSD (indicating reduced vagal tone) will show a significantly greater increase in HRV and reduction in anxiety scores after four weeks of daily L. rhamnosus JB-1 supplementation compared to individuals with high baseline RMSSD, who will show minimal or no change.
Mechanistic Rationale
L. rhamnosus JB-1 modulates anxiety via vagus nerve‑dependent GABA receptor signaling in the gut[3]. We propose that the magnitude of this effect is gated by the host’s intrinsic vagal activity: low vagal tone reflects a system with greater reserve for afferent amplification, allowing probiotic‑induced enterochromaffin cell serotonin release to robustly drive vagal firing and subsequent HRV elevation. In contrast, high baseline vagal tone may already saturate the afferent pathway, limiting further HRV gains and potentially triggering homeostatic feedback that blunts anxiolytic outcomes. This gating could involve strain‑specific production of short‑chain fatty acids (e.g., lactate) that enhance colonic serotonin synthesis, a step shown to be HRV‑responsive in vagal stimulation studies[8].
Predictions
- Primary: Change in RMSSD from baseline to week 4 will be positively correlated with baseline RMSSD deficit (i.e., larger gains in those starting low).
- Secondary: Anxiety reduction (ΔSTAI‑6) will mediate the relationship between HRV change and clinical outcome, with mediation strength highest in the low‑tone subgroup.
- Exploratory: Fecal lactate and serotonin concentrations will rise disproportionately in low‑tone responde





























